Showing 1 - 10 results of 10 for search 'E. A. Dudko', query time: 0.01s Refine Results
  1. 1
    Parameters of Specific Antibody Interaction with Pgp in T-Cell Leukemia Jurkat Cells

    Parameters of Specific Antibody Interaction with Pgp in T-Cell Leukemia Jurkat Cells by T. A. Bogush, E. A. Dudko, E. A. Bogush, A. YU. Baryshnikov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Glutoxime, as an Inhibitor of Multiple Drug Resistance Phenotype Associated with Pgp Expression

    Glutoxime, as an Inhibitor of Multiple Drug Resistance Phenotype Associated with Pgp Expression by T. A. Bogush, E. A. Dudko, E. A. Bogush, V. YU. Kirsanov, V. G. Antonov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Expression of Estrogen Receptors β and ß<sub>1</sub> in Tissue of Human Non-Small Cell Lung Cancer

    Expression of Estrogen Receptors β and ß<sub>1</sub> in Tissue of Human Non-Small Cell Lung Cancer by A. S. Shaturova, T. A. Bogush, E. A. Dudko, G. YU. Chemeris, R. YU. Ramanauskaite, I. D. Kalganov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Tamoxifen Molecular Targets Different From Estrogen Receptors

    Tamoxifen Molecular Targets Different From Estrogen Receptors by T. A. Bogush, E. A. Dudko, E. A. Bogush, B. E. Polotsky, S. A. Tyulyandin, M. I. Davydov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer

    The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer by T. A. Bogush, E. A. Dudko, E. A. Bogush, B. E. Polotsky, S. A. Tyulyandin, M. I. Davydov

    Published 2014-07-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs

    ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs by T. A. Bogush, A. S. Popova, E. A. Dudko, E. A. Bogush, A. S. Tyulyandina, S. A. Tyulyandin, M. I. Davydov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Discordance of Estrogen Receptor Status Between Primary and Metastatic Breast Cancer: Possible Reasons and Prognostic Value

    Discordance of Estrogen Receptor Status Between Primary and Metastatic Breast Cancer: Possible Reasons and Prognostic Value by T. A. Bogush, A. S. Popova, E. A. Dudko, E. O. Ignatova, B. E. Polotsky, S. A. Tjuljandin, M. I. Davydov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Estrogen Receptor Expression in Tumors Different from Breast Cancer

    Estrogen Receptor Expression in Tumors Different from Breast Cancer by T. A. Bogush, E. A. Dudko, A. A. Beme, E. A. Bogush, B. E. Polotsky, S. A. Tjuljandin, M. I. Davydov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    New Data on Molecular Targets of Tamoxifen Besides Estrogen Receptors, Their Clinical Significancy

    New Data on Molecular Targets of Tamoxifen Besides Estrogen Receptors, Their Clinical Significancy by T. A. Bogush, B. B. Polezhaev, E. A. Dudko, E. A. Bogush, V. Yu. Kirsanov, B. E. Polotsky, S. A. Tjuljandin, M. I. Davydov

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF KI67 DYNAMIC CHANGE DURING PREOPERATIVE ENDOCRINE THERAPY IN BREAST CNACER PATIENTS

    PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF KI67 DYNAMIC CHANGE DURING PREOPERATIVE ENDOCRINE THERAPY IN BREAST CNACER PATIENTS by M. V. Rodionova, I. K. Vorotnikov, V. V. Rodionov, E. A. Dudko, N. V. Chkhivadze, V. V. Kometova, D. A. Ryabchikov, E. V. Oshkina, A. S. Ozherelyev, T. А. Bogush

    Published 2016-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: